Edition:
India

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

3.84USD
13 Dec 2019
Change (% chg)

$0.01 (+0.26%)
Prev Close
$3.83
Open
$3.84
Day's High
$3.86
Day's Low
$3.75
Volume
169,489
Avg. Vol
249,086
52-wk High
$4.57
52-wk Low
$1.96

Latest Key Developments (Source: Significant Developments)

UroGen Pharma Announces Exclusive License Agreement With Agenus Inc To Advance Treatment Of Urinary Tract Cancers
Monday, 11 Nov 2019 

Nov 11 (Reuters) - Urogen Pharma Ltd ::UROGEN PHARMA ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH AGENUS INC TO ADVANCE TREATMENT OF URINARY TRACT CANCERS.UROGEN PHARMA - TO DEVELOP AND COMMERCIALIZE ZALIFRELIMAB WITH UGN-201 FOR HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER.UROGEN PHARMA LTD - IN EXCHANGE FOR WORLDWIDE EXCLUSIVE LICENSE TO AGEN1884 AGENUS WILL RECEIVE AN UPFRONT PAYMENT OF $10 MILLION.UROGEN PHARMA LTD - AGENUS MAY RECEIVE UP TO $115 MILLION FOR ACHIEVING CERTAIN CLINICAL DEVELOPMENT AND REGULATORY MILESTONES RELATED TO AGEN1884.UROGEN PHARMA LTD - AGENUS MAY RECEIVE UP TO $85 MILLION UPON ACHIEVING CERTAIN COMMERCIAL MILESTONES RELATED TO AGEN1884.UROGEN PHARMA LTD - WILL BE RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES OF AGEN1884.UROGEN PHARMA - WORLDWIDE LICENSE DOES NOT INCLUDE ARGENTINA, BRAZIL, CHILE, COLOMBIA, PERU, VENEZUELA.  Full Article

Agenus Q3 Loss Per Share $0.33
Monday, 4 Nov 2019 

Nov 4 (Reuters) - Agenus Inc ::Q3 LOSS PER SHARE $0.33.ENDED THIRD QUARTER OF 2019 WITH CASH BALANCE OF $93 MILLION AS COMPARED TO $53 MILLION AT DEC 31, 2018.QTRLY TOTAL REVENUE $19.9 MILLION VERSUS $12.8 MILLION.  Full Article

Agenus Q2 Loss Per Share $0.38
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Agenus Inc ::AGENUS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.38.  Full Article

Agenus Reports Q1 Results
Thursday, 9 May 2019 

May 9 (Reuters) - Agenus Inc ::AGENUS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 EARNINGS PER SHARE $0.14.Q1 REVENUE $80 MILLION.GSK'S SHINGRIX SALES CONTINUE TO GROW; PROJECTED TO BE ABOUT $1.3 BILLION IN 2019.2019 INDS ARE ON TRACK.PARTNERSHIP AND PRIVATE FINANCING DISCUSSIONS ARE UNDERWAY.  Full Article

Gilead Sciences And Agenus Enter Into Collaboration
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Agenus Inc ::GILEAD AND AGENUS ENTER INTO COLLABORATION TO DEVELOP IMMUNO-ONCOLOGY THERAPIES.AGENUS INC - AGENUS WILL RECEIVE $150 MILLION UPON CLOSING.AGENUS INC - AGREEMENT ALSO INCLUDES APPROXIMATELY $1.7 BILLION IN POTENTIAL FUTURE FEES AND MILESTONES.AGENUS INC - GILEAD WILL RECEIVE WORLDWIDE EXCLUSIVE RIGHTS TO AGEN1423, WHICH HAS AN ESTIMATED IND FILING BY YEAR-END 2018.AGENUS INC - GILEAD WILL ALSO RECEIVE EXCLUSIVE OPTION TO LICENSE TWO ADDITIONAL PROGRAMS: AGEN1223 AND AGEN2373..AGENUS INC - AGENUS HAS FILED IND FOR AGEN1223 AND HAS AN ESTIMATED IND FILING FOR AGEN2373 IN FIRST HALF OF 2019..AGENUS INC - AGENUS WILL BE RESPONSIBLE FOR DEVELOPING OPTION PROGRAMS UP TO OPTION DECISION POINTS.  Full Article

Agenus Q3 Loss Per Share $0.29
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Agenus Inc ::AGENUS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.29.Q3 REVENUE $13 MILLION.PARTNERSHIP DISCUSSIONS PROGRESSING TOWARDS CLOSURE.LEAD IDENTIFIED FOR IND FILING; PRIVATE FINANCING AND PLANS FOR IPO UNDERWAY.  Full Article

Agenus Receives Milestone Payment From Incyte
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Agenus Inc ::AGENUS RECEIVES MILESTONE PAYMENT FROM INCYTE.AGENUS INC - PAYMENT OF $5M RECEIVED FOR INITIATION OF PHASE 1 TRIAL OF LAG-3 ANTIBODY.AGENUS - ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $505 MILLION IN POTENTIAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES FROM INCYTE.  Full Article

Agenus Reports Q4 Loss Per Share $0.35
Thursday, 15 Mar 2018 

March 15 (Reuters) - Agenus Inc ::AGENUS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.35.Q4 EARNINGS PER SHARE VIEW $-0.29 -- THOMSON REUTERS I/B/E/S.CASH, AND CASH EQUIVALENTS WERE $60.2 MILLION AT DECEMBER 31, 2017.QTRLY REVENUE $8.4 MILLION VERSUS $5.6 MILLION.  Full Article

Agenus Announces $230 Mln Royalty Monetization With Healthcare Royalty Partners
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Agenus Inc ::AGENUS INC. ANNOUNCES $230 MILLION ROYALTY MONETIZATION WITH HEALTHCARE ROYALTY PARTNERS.AGENUS INC - TRANSACTION IS COMPRISED OF $190 MILLION OF CASH PROCEEDS AT CLOSING PLUS UP TO $40 MILLION IN MILESTONE PAYMENTS.AGENUS INC - AGENUS WILL USE PART OF THE PROCEEDS TO REDEEM ITS ROYALTY BOND FROM OBERLAND, AMONG OTHERS.AGENUS INC - IN EVENT THAT CERTAIN SALES MILESTONES ARE NOT MET, AGENUS WILL OWE HCR APPROXIMATELY $26 MILLION IN 2021.  Full Article